23andMe said it's started exploring strategic alternatives, including a possible sale. The company released third-quarter ...

A pioneer in genetic heritage services, 23andMe has seen much of its share price wiped out in the past year as it struggles ...

By the 2023 fiscal year, 23andMe had reported a net loss of $312 million and its individual share price has plummeted a ...

23andMe Holding Co. ( ME, Financials) announced that its board's Special Committee is reviewing strategic alternatives, ...

Genetic testing pioneer 23andMe is looking at strategic alternatives, including a possible sale, it said Tuesday, months ...

Me (ME) forms special board committee to explore strategic alternatives, including sale, restructuring, or business ...

The struggling genetic-testing 23andMe is looking for a buyer for the virtual-care business it acquired in 2021, Business ...

Company Notes Continued Concerns Regarding Liquidity and Consideration of Potential Ways to Address Operational and Financial ...

The Board of Directors of 23andMe previously formed the Special Committee, which is comprised of independent directors, to review strategic alternatives that may be available to 23andMe. The Special ...

At-home DNA testing is no longer in high demand — and critics have raised concerns about unreliable tests and privacy.

The Special Committee of the Board of Directors of 23andMe Holding Co. (Nasdaq: ME) ("23andMe" or the "Company"), a leading human genetics company ...

Manhattan Associates' 2025 outlook missed estimates. The provider of supply-chain and omnichannel-commerce solutions said it expects adjusted per-share earnings of $4.45 to $4.55 on revenue of $1.06 ...